Compare Genuine Parts Company (GPC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Zimmer Biomet Holdings Inc — how do they compare? Genuine Parts Company trades at $125.22 (market cap $16.65B), while Zimmer Biomet Holdings Inc trades at $93.31 (market cap $17.44B). The key difference: Genuine Parts Company and Zimmer Biomet Holdings Inc are close in size by market cap, and Genuine Parts Company pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| GPC | ZBH | |
|---|---|---|
Market Cap | $16.65B | $17.44B |
Sector | Consumer Cyclical | Health |
52-Week High | $149.26 | $107.71 |
52-Week Low | $92.47 | $79.58 |
Enterprise Value | $22.87B | $24.49B |
Dividend Yield | 3.51% | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genuine Parts Company (GPC) trades at $122.16, down 1.1% on the day, with a bullish technical signal supported by moving averages and oscillators. Fundamentally, the company shows strong revenue growth to $24.3B in 2025 but faces significant margin compression, with net income plummeting to $66M (0.27% margin) from $904M the prior year. The stock carries a high P/E of 275 but reasonable P/S of 0.68, while analysts maintain a consensus 'Buy' rating with a $133 price target. Recent news highlights GPC's upcoming Q2 2026 earnings report on July 21, 2026, and its status as a Dividend King with 70 consecutive years of dividend increases.
The outlook presents a mixed picture: technical strength and dividend reliability support the stock, while deteriorating profitability and high valuation multiples pose significant risks. Investment opportunity lies in potential earnings recovery and continued dividend growth, but investors face headwinds from margin pressure and elevated P/E ratio requiring careful monitoring of upcoming quarterly results.
Zimmer Biomet (ZBH) trades at $91.03, down 3.24% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue growth has climbed from $6.9B in 2022 to $8.2B in 2025, though net income margin dipped to 8.56%. Recent corporate developments include a $140M acquisition and expansion in India, supporting long-term growth initiatives.
The outlook remains cautiously optimistic with a consensus price target of $97.67, implying 7% upside. Key opportunities include operational efficiency and market share gains, while risks involve debt levels rising to 32.57% of assets and competitive pressures in medical technology. Earnings on August 5 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
